Charles Lin
Affiliations: | 2009-2013 | Biology | Massachusetts Institute of Technology, Cambridge, MA, United States |
Google:
"Charles Lin"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Yao Y, Fong Ng J, Park WD, et al. (2023) CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma. Blood |
| Morelli E, Fulciniti M, Samur MK, et al. (2022) A MIR17HG-derived Long Noncoding RNA Provides an Essential Chromatin Scaffold for Protein Interaction and Myeloma Growth. Blood |
| Hsu A, Duan Q, Day DS, et al. (2022) Targeting transcription in heart failure via CDK7/12/13 inhibition. Nature Communications. 13: 4345 |
| Eagle K, Harada T, Kalfon J, et al. (2022) Transcriptional plasticity drives leukemia immune escape. Blood Cancer Discovery |
| Harada T, Heshmati Y, Kalfon J, et al. (2022) A distinct core regulatory module enforces oncogene expression in KMT2A-rearranged leukemia. Genes & Development. 36: 368-389 |
| Eagle K, Jiang Y, Shi X, et al. (2022) An oncogenic enhancer encodes selective selenium dependency in AML. Cell Stem Cell |
| Arabzade A, Zhao Y, Varadharajan S, et al. (2021) ZFTA-RELA Dictates Oncogenic Transcriptional Programs to Drive Aggressive Supratentorial Ependymoma. Cancer Discovery |
| Sheppard HE, Dall'Agnese A, Park WD, et al. (2021) Targeted brachyury degradation disrupts a highly specific autoregulatory program controlling chordoma cell identity. Cell Reports. Medicine. 2: 100188 |
| Poon E, Liang T, Jamin Y, et al. (2020) Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma. The Journal of Clinical Investigation |
| Mercado N, Schutzius G, Kolter C, et al. (2019) IRF2 is a master regulator of human keratinocyte stem cell fate. Nature Communications. 10: 4676 |